Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Phase I/II results announced for Genzyme Molecular Oncology's melanoma vaccine

Jan. 14, 2003

New-generation TTS product cleared for human testing

Jan. 13, 2003

ZymoGenetics and Novo Nordisk join forces to develop IL-21

Jan. 13, 2003

Antitumor activity reported for BioVex's OncoVEX(GM-CSF)

Jan. 10, 2003

Medarex files IND for MDX-070

Jan. 8, 2003

IND filed for EOS-200-4

Jan. 7, 2003

Crucell regains rights to anti-CD46 antibody

Jan. 7, 2003

G17DT granted orphan drug status in Australia for gastric and pancreatic cancers

Jan. 3, 2003

Campath enters phase I/II trial in NHL

Jan. 3, 2003

NeoPharm seeks FDA guidance on IL-13-PE38 trial design and registration plan

Dec. 30, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...